1. Scrip
  2. >>Business
  3. >>Deals

Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs

Acquires Swiss Biotech To Expand Neurology Pipeline

 
• By Kevin Grogan

Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.

merck kgaa
The Darmstadt-based group is looking for bolt-ons • Source: Merck KGaA

It comes as no great surprise that Chord Therapeutics SA, the Swiss biotech which has been looking at the potential of cladribine in rare diseases, has been snapped up by Merck KGaA given that the German group has been been selling an oral version of the well-established chemotherapy as Mavenclad for the treatment of multiple sclerosis for the past few years.

Chord only emerged from stealth in October 2020 with a $16m series A cash injection from healthcare venture capital firm...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By Joseph Haas

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company

 
• By Joseph Haas

Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy

 
• By Alaric DeArment

The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.

More from Business